DETAILED ACTION
Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
Information Disclosure Statement
The Information Disclosure Statements filed on 11/20/2024, 9/11/2025 have been entered and considered. Initialed copies of the form PTO-1449 are enclosed with this action.
Restriction-Election/Status of claims
On 5/13/2026, the applicant elected SNV1 for Election 1, InDel4 for Election 2, and the combination of SNV1, InDel4, and SNV95 for Election 3, without traverse.
Up on further consideration, SNV1, InDel4, and SNV95 are examined individually and as a combination.
In summary, claims 1-7 are pending and examined in this office action. Non-elected species are withdrawn.
Priority
Instant application 18810533, filed 08/21/2024, is a Continuation of PCT/JP2023/006427, filed 02/22/2023, and claims foreign priority to 2022-027284, filed 02/24/2022.
The certified copy of the foreign priority was received, but an English translation is missing.
Thus, the priority date of 2/14/2022 is not recognized until the English translation is received.
Claim Objections
Claims 1 and 7 are objected to because:
The independent claims recite “a chromosome Nt09 in a reference genome sequence of K326 of Nicotiana tabacum”.
According to 37 CFR 1.57, the incorporation of essential material by reference to an unpublished U.S. application, foreign application or patent, or to a publication is improper.
According to Nicotiana tabacum genome assembly ASM71507v2 - NCBI - NLM (PDF also attached), genome sequence of K326 of Nicotiana tabacum has different versions, currently the updated version is version 2. Version 1 is different from version 2.
Accordingly, “a chromosome Nt09 in a reference genome sequence of K326 of Nicotiana tabacum” or “a reference genome sequence of K326 of Nicotiana tabacum” are modifiable in content and thus not static sources of information.
Appropriate corrections are required.
The most reliable static information is SEQ ID NOs in a sequence listing.
Claim 1 is objected for following informalities:
In the claim, “SNV”, “Nt09”, “InDel” appear in a claim for the first time. Each of the full names should be recited, followed by the abbreviation in a ().
In addition, the following suggestions are made for correcting informalities:
It is suggested to recite --- tobacco cultivar Matsukawa --- instead of the “Matsukawa”.
It is suggested to recite --- tables 1-2 below --- instead of the “tables below”.
In the 3rd para, the “markers” should be --- the markers ---.
In the 5th para, the “InDel” should be in plural form: --- insertions/deletions (InDels) ---.
In the last para, the “insertion/deletion” should be --- each of the InDels ---.
Claims 1 and 7 are objected for following informalities:
In the claims, the “a chromosome Nt09” should be --- the chromosome Nt09 ---.
See the requirement of 37 CFR 1.71(a) for “full, clear, and exact terms”.
Appropriate correction is required.
The claims are also rejected below for indefiniteness.
Claim Rejections - 35 USC § 112
Enablement/Lacking Deposit
The following is a quotation of the first paragraph of 35 U.S.C. 112(a):
(a) IN GENERAL—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention.
Claims 1-7 are rejected under 35 U.S.C. 112(a), as failing to comply with the enablement requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention.
As analyzed below in the 112(b) rejection, by BRI cultivar Matsukawa (Kanto) is interpreted as cultivar Matsukawa, of all types and variations.
Claims are drawn to methods of using (to develop new tobacco cultivars), and resultant products, of tobacco cultivar Matsukawa.
By the examiner’s search, only Nicotiana tabacum (also called common tobacco) cultivar K326 has been partially sequenced. See Nicotiana tabacum genome assembly ASM71507v2 - NCBI - NLM. PDF also attached.
Tobacco cultivar Matsukawa, or cultivar Matsukawa Kanto, is not a new cultivar, but had/has not been deposited, sequenced, or characterized, at least for low reversion type low nornicotine content. The specification does not provide deposit information, or sequence (even partial sequence) of cultivar Matsukawa.
Thus, cultivar Matsukawa appears to be a newly characterized biological material. Since the seed of cultivar Matsukawa is essential to the claimed invention, it must be obtainable by a repeatable method set forth in the specification or otherwise be readily available to the public. If a seed is not so obtainable or available, a deposit thereof may satisfy the requirements of 35 U.S.C. 112. The specification does not disclose a repeatable process to obtain the exact same seed in each occurrence and it is not apparent if such a seed is readily available to the public.
If the deposit has been made under the terms of the Budapest Treaty, then a statement, affidavit or declaration by Applicants, or a statement by an attorney of record over his or her signature and registration number, or someone empowered to make such a statement, stating that the specific strain has been deposited under the Budapest Treaty and that the strain will be irrevocably and without restriction released to the public upon the issuance of a patent, and will be publicly available for the enforceable life of the patent, would satisfy the deposit requirement made herein.
If the deposit has not been made under the Budapest Treaty, then in order to certify that the deposit meets the criteria set forth in 37 C.F.R. 1.801-1.809 and MPEP 2402-2411.05, Applicants may provide assurance of compliance by statement, affidavit or declaration, or by someone empowered to make the same, or by a statement by an attorney of record over his or her signature and registration number, showing that
(a) during the pendency of the application, access to the invention will be afforded to the Commissioner upon request;
(b) all restrictions upon availability to the public will be irrevocably removed upon granting of the patent for the enforceable life of the patent in accordance with 37 CFR § 1.808(a)(2);
(c) the deposit will be maintained in a public depository for a period of 30 years or 5 years after the last request or for the enforceable life of the patent, whichever is longer; and
(d) the viability of the biological material at the time of deposit will be tested (see 37 CFR 1.807).
In addition, the deposit information set forth in 37 CFR 1.809(d) should be added to the specification. See 37 C.F.R. 1.801-1.809 for additional explanation of these requirements.
Alternatively, the applicant can provide sequence information, in form of SEQ ID NO(s), at least partial sequences as markers or primers, that are sufficient to distinguish cultivar Matsukawa from common tobacco, and all other tobacco cultivars, and are readily searchable and usable, for one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention. See MPEP 2164.
Note: regarding claim 7, by examiner’s search, SEQ ID NO: 2, and its encoding sequence, had been taught in the art (multiple references) as a sequence of Nicotiana tabacum/common tobacco. Thus, SEQ ID NO: 2 does not distinguish cultivar Matsukawa from common tobacco, or any other tobacco cultivars. Additional sequences, markers or primers, are required. See “Sequence Matches” (at least 86 duplicates of 100% identical) at the end of office action.
Indefiniteness
The following is a quotation of 35 U.S.C. 112(b):
(b) CONCLUSION—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention.
Claims 1-7 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor, or for pre-AIA the applicant regards as the invention.
There are multiple issues:
Claims recite a term “Matsukawa (Kanto)”, multiple claims, multiple times.
According to Arai et al (The origin and distribution of ‘Kokubu’-type splice-site mutations of the MLO genes in tobacco varieties. Breeding Science 72: 248-256, 2022, not prior art), there are at least 2 known cultivars named Matsukawa, Matsukawa Kanto and Matsukawa Ohkoshichikanari (p251-252, Table 2).
A broad range or limitation together with a narrow range or limitation that falls within the broad range or limitation (in the same claim) is considered indefinite, since the resulting claim does not clearly set forth the metes and bounds of the patent protection desired. See MPEP § 2173.05(c).
In the present instance, claims recite the broad recitation Matsukawa, and the claims also recite Kanto in ()s, which is the narrower statement of the range/limitation. In another word, the “(Kanto)” is narrower than and is a species of “Matsukawa”. It is unclear if the “(Kanto)” means to be Matsukawa Kanto or means to be an example of Matsukawa, or means to be a claim requirement. The metes and bounds are unclear.
Appropriate corrections and clarifications are required.
Dependent claims do not cure the deficiency.
For compact prosecution, by BRI, cultivar “Matsukawa (Kanto)” has to be interpreted as cultivar Matsukawa. If the applicant clearly intends to mean Kanto, it is recommended to recite --- cultivar Matsukawa Kanto ---.
Independent claims 1 and 7 recites “wherein markers indicated by SNV are each a marker based on single nucleotide variation present at a position corresponding to each shown position on a chromosome Nt09 in a reference genome sequence of K326 of Nicotiana tabacum, a "Base" indicates a base in Matsukawa (Kanto), markers indicated by InDel are each a marker based on insertion or deletion present at a position corresponding to each shown position on the chromosome Nt09 in the reference genome sequence, and "Insertion/Deletion" indicates whether the insertion or the deletion is present or not in Matsukawa (Kanto).
By the examiner’s search, the SNVs (SNV1 and SNV95 are elected) in Tables 1 and 3, and the InDels (InDel4 is elected) in Tables 2 and 4, do not generate any meaningful search results in the art.
As analyzed above, the specification does not provide any sequences, deposit, not even a version of the “reference genome sequence of K326 of Nicotiana tabacum”. Hence, the “positions on Nt09” and the “Base” in Tables 1 and 3 do not have clear meanings. The “positions on Nt09” and the “insertion/deletion” in Tables 2 and 4 also do not have clear meanings.
As a result, the SNVs in Tables 1-3 and the InDels in Tables 2-4, are not art searchable and are not clearly defined by the specification. Therefore, they do not have art recognized meanings.
Appropriate corrections and clarifications are required for one skill in the art to make and use the claimed invention.
Dependent claims do not cure the deficiencies.
Claim 1 recites “at least one marker which is of Matsukawa (Kanto), which is selected from tables below, and which allows Matsukawa (Kanto) to be distinguished from the another variety or the mutant of the another variety, wherein markers indicated by SNV are each a marker based on single nucleotide variation present at a position corresponding to each shown position on a chromosome Nt09 in a reference genome sequence of K326 of Nicotiana tabacum”. Claims 5 and 7 have similar recitations.
The examiner notices that
Table 3 differs Table 1 by excluding SNVs 1, 3, 6, 13-14, 21, 26, 29, 38, 42-43, 46, 48, 54-55, 57-58, 62-66, 68, 71-73, 81, 83, 89-91, and 95 (otherwise includes all other SNVs of Table 1).
Table 4 differs Table 2 by excluding InDels 3, 9, 11, 13-15, 17-18, and 20 (otherwise includes all other InDels of Table 2).
From the context of claim 7, another low nornicotine content tobacco plant (other than Matsukawa) comprises and requires the SNVs and InDels except the exclusions in Tables 3 and 4.
Claim 1 requires that at least one marker, a SNV in Table 1 and a InDel in Table 2, is required to distinguish Matsukawa from the another tobacco.
Thus, Both Matsukawa and tobacco plant (other than Matsukawa) require the the SNVs and InDels except the exclusions in Tables 3 and 4.
In another word, the “at least one marker” recited in claim 1 cannot distinguish Matsukawa from the another tobacco. In another word, the claims are contradicting among themselves.
Appropriate corrections and clarifications are required for one skill in the art to make and use the claimed invention.
Dependent claims do not cure the deficiencies.
Remarks
As analyzed above, claims are deemed indefinite and not enabled. Please also see the prosecution of application 17965450/USP12239090, filed by the applicant Japan Tobacco Inc. SEQ ID NOs are claimed.
For compact prosecution, the examiner performed limited searches.
By the examiner’s search, only Nicotiana tabacum (also called common tobacco) cultivar K326 has been partially sequenced. See Nicotiana tabacum genome assembly ASM71507v2 - NCBI - NLM. PDF also attached.
Tobacco cultivar Matsukawa, or cultivar Matsukawa Kanto, is not a new cultivar, but had/has not been deposited, sequenced, or characterized.
However, the examiner cannot perform specific and meaningful searches based on the claims and specification. Once the issues are overcome, further search will be performed.
Sequence Matches
Against instant SEQ ID NO:2
Against Polypeptides
RESULT 1
US-10-934-944-182
(NOTE: this sequence has 86 duplicates in the database searched.
See complete list at the end of this report)
Sequence 182, US/10934944
Patent No. 7812227
GENERAL INFORMATION
APPLICANT: Xu, Dongmei
TITLE OF INVENTION: Cloning of Cytochrome P450 Genes From Nicotiana
FILE REFERENCE: 07678/141008
CURRENT APPLICATION NUMBER: US/10/934,944
CURRENT FILING DATE: 2004-09-03
PRIOR APPLICATION NUMBER: 10/686,947
PRIOR FILING DATE: 2003-10-16
PRIOR APPLICATION NUMBER: 60/503,989
PRIOR FILING DATE: 2003-09-18
PRIOR APPLICATION NUMBER: 60/485,368
PRIOR FILING DATE: 2003-07-08
PRIOR APPLICATION NUMBER: 10/387,346
PRIOR FILING DATE: 2003-03-12
PRIOR APPLICATION NUMBER: 10/340,861
PRIOR FILING DATE: 2003-01-10
PRIOR APPLICATION NUMBER: 10/293,252
PRIOR FILING DATE: 2002-11-13
PRIOR APPLICATION NUMBER: 60/418,933
PRIOR FILING DATE: 2002-10-16
PRIOR APPLICATION NUMBER: 60/363,684
PRIOR FILING DATE: 2002-03-12
PRIOR APPLICATION NUMBER: 60/347,444
PRIOR FILING DATE: 2002-01-11
PRIOR APPLICATION NUMBER: 60/337,684
PRIOR FILING DATE: 2001-11-13
NUMBER OF SEQ ID NOS: 387
SEQ ID NO 182
LENGTH: 517
TYPE: PRT
ORGANISM: Nicotiana tabacum
Query Match 100.0%; Score 2733; Length 517;
Best Local Similarity 100.0%;
Matches 517; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 MLSPIEAIVGLVTFTFLFFFLWTKKSQKPSKPLPPKIPGGWPVIGHLFHFNDDGDDRPLA 60
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 1 MLSPIEAIVGLVTFTFLFFFLWTKKSQKPSKPLPPKIPGGWPVIGHLFHFNDDGDDRPLA 60
Qy 61 RKLGDLADKYGPVFTFRLGLPLVLVVSSYEAVKDCFSTNDAIFSNRPAFLYGDYLGYNNA 120
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 61 RKLGDLADKYGPVFTFRLGLPLVLVVSSYEAVKDCFSTNDAIFSNRPAFLYGDYLGYNNA 120
Qy 121 MLFLANYGPYWRKNRKLVIQEVLSASRLEKFKHVRFARIQASIKNLYTRIDGNSSTINLT 180
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 121 MLFLANYGPYWRKNRKLVIQEVLSASRLEKFKHVRFARIQASIKNLYTRIDGNSSTINLT 180
Qy 181 DWLEELNFGLIVKMIAGKNYESGKGDEQVERFKKAFKDFMILSMEFVLWDAFPIPLFKWV 240
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 181 DWLEELNFGLIVKMIAGKNYESGKGDEQVERFKKAFKDFMILSMEFVLWDAFPIPLFKWV 240
Qy 241 DFQGHVKAMKRTFKDIDSVFQNWLEEHINKREKMEVNAEGNEQDFIDVVLSKMSNEYLGE 300
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 241 DFQGHVKAMKRTFKDIDSVFQNWLEEHINKREKMEVNAEGNEQDFIDVVLSKMSNEYLGE 300
Qy 301 GYSRDTVIKATVFSLVLDAADTVALHINWGMALLINNQKALTKAQEEIDTKVGKDRWVEE 360
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 301 GYSRDTVIKATVFSLVLDAADTVALHINWGMALLINNQKALTKAQEEIDTKVGKDRWVEE 360
Qy 361 SDIKDLVYLQAIVKEVLRLYPPGPLLVPHENVEDCVVSGYHIPKGTRLFANVMKLQRDPK 420
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 361 SDIKDLVYLQAIVKEVLRLYPPGPLLVPHENVEDCVVSGYHIPKGTRLFANVMKLQRDPK 420
Qy 421 LWSDPDTFDPERFIATDIDFRGQYYKYIPFGSGRRSCPGMTYALQVEHLTMAHLIQGFNY 480
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 421 LWSDPDTFDPERFIATDIDFRGQYYKYIPFGSGRRSCPGMTYALQVEHLTMAHLIQGFNY 480
Qy 481 RTPNDEPLDMKEGAGITIRKVNPVELIIAPRLAPELY 517
|||||||||||||||||||||||||||||||||||||
Db 481 RTPNDEPLDMKEGAGITIRKVNPVELIIAPRLAPELY 517
One of the 86 duplicates
US-11-116-881C-3
Filing date in PALM: 2005-04-27
Sequence 3, US/11116881C
Patent No. 7700834
GENERAL INFORMATION
APPLICANT: XU, DONGMEI
APPLICANT: NIELSEN, MARK T.
TITLE OF INVENTION: NICOTIANA NUCLEIC ACID MOLECULES AND USES THEREOF
FILE REFERENCE: 20210-070001
CURRENT APPLICATION NUMBER: US/11/116,881C
CURRENT FILING DATE: 2005-04-27
PRIOR APPLICATION NUMBER: 11/110,062
PRIOR FILING DATE: 2005-04-19
PRIOR APPLICATION NUMBER: 60/665,451
PRIOR FILING DATE: 2005-03-24
PRIOR APPLICATION NUMBER: 60/665,097
PRIOR FILING DATE: 2005-03-24
PRIOR APPLICATION NUMBER: 60/646,764
PRIOR FILING DATE: 2005-01-25
PRIOR APPLICATION NUMBER: PCT/US04/34218
PRIOR FILING DATE: 2004-10-15
PRIOR APPLICATION NUMBER: PCT/US04/34065
PRIOR FILING DATE: 2004-10-15
PRIOR APPLICATION NUMBER: 10/943,507
PRIOR FILING DATE: 2004-09-17
PRIOR APPLICATION NUMBER: 10/934,944
PRIOR FILING DATE: 2004-09-03
PRIOR APPLICATION NUMBER: 60/607,357
PRIOR FILING DATE: 2004-09-03
PRIOR APPLICATION NUMBER: 60/566,235
PRIOR FILING DATE: 2004-04-29
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 2303
SEQ ID NO 3
LENGTH: 517
TYPE: PRT
ORGANISM: Nicotiana tabacum
Against Encoding Polynucleotides
RESULT 1
US-11-110-062-3
(NOTE: this sequence has 23 duplicates in the database searched.
See complete list at the end of this report)
Sequence 3, US/11110062
Patent No. 7700851
GENERAL INFORMATION
APPLICANT: Xu, Dongmei
TITLE OF INVENTION: Cloning of Cytochrome P450 Genes From Nicotiana
FILE REFERENCE: 07678/141013
CURRENT APPLICATION NUMBER: US/11/110,062
CURRENT FILING DATE: 2005-04-19
PRIOR APPLICATION NUMBER: 60/665,451
PRIOR FILING DATE: 2005-03-24
PRIOR APPLICATION NUMBER: 60/665,097
PRIOR FILING DATE: 2005-03-24
PRIOR APPLICATION NUMBER: 60/646,764
PRIOR FILING DATE: 2005-01-25
PRIOR APPLICATION NUMBER: 60/607,357
PRIOR FILING DATE: 2004-09-03
PRIOR APPLICATION NUMBER: 60/566,235
PRIOR FILING DATE: 2004-04-29
PRIOR APPLICATION NUMBER: 10/934,944
PRIOR FILING DATE: 2004-09-03
PRIOR APPLICATION NUMBER: 10/943,507
PRIOR FILING DATE: 2004-09-17
PRIOR APPLICATION NUMBER: 60/503,989
PRIOR FILING DATE: 2003-09-18
PRIOR APPLICATION NUMBER: 60/485,368
PRIOR FILING DATE: 2003-07-08
PRIOR APPLICATION NUMBER: 60/418,933
PRIOR FILING DATE: 2002-10-16
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 29
SEQ ID NO 3
LENGTH: 1554
TYPE: DNA
ORGANISM: Tobacco Nicotine Demethylase Gene Coding Sequence
Alignment Scores:
Length: 1554
Score: 2733.00 Matches: 517
Percent Similarity: 100.0% Conservative: 0
Best Local Similarity: 100.0% Mismatches: 0
Query Match: 100.0% Indels: 0
Gaps: 0
US-18-810-533-2 (1-517) x US-11-110-062-3 (1-1554)
Qy 1 MetLeuSerProIleGluAlaIleValGlyLeuValThrPheThrPheLeuPhePhePhe 20
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 1 ATGCTTTCTCCCATAGAAGCCATTGTAGGACTAGTAACCTTCACATTTCTCTTCTTCTTC 60
Qy 21 LeuTrpThrLysLysSerGlnLysProSerLysProLeuProProLysIleProGlyGly 40
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 61 CTATGGACAAAAAAATCTCAAAAACCTTCAAAACCCTTACCACCGAAAATCCCCGGAGGA 120
Qy 41 TrpProValIleGlyHisLeuPheHisPheAsnAspAspGlyAspAspArgProLeuAla 60
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 121 TGGCCGGTAATCGGCCATCTTTTCCACTTCAATGACGACGGCGACGACCGTCCATTAGCT 180
Qy 61 ArgLysLeuGlyAspLeuAlaAspLysTyrGlyProValPheThrPheArgLeuGlyLeu 80
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 181 CGAAAACTCGGAGACTTAGCTGACAAATACGGCCCCGTTTTCACTTTTCGGCTAGGCCTT 240
Qy 81 ProLeuValLeuValValSerSerTyrGluAlaValLysAspCysPheSerThrAsnAsp 100
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 241 CCCCTTGTCTTAGTTGTAAGCAGTTACGAAGCTGTAAAAGACTGTTTCTCTACAAATGAC 300
Qy 101 AlaIlePheSerAsnArgProAlaPheLeuTyrGlyAspTyrLeuGlyTyrAsnAsnAla 120
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 301 GCCATTTTTTCCAATCGTCCAGCTTTTCTTTACGGCGATTACCTTGGCTACAATAATGCC 360
Qy 121 MetLeuPheLeuAlaAsnTyrGlyProTyrTrpArgLysAsnArgLysLeuValIleGln 140
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 361 ATGCTATTTTTGGCCAATTACGGACCTTACTGGCGAAAAAATCGAAAATTAGTTATTCAG 420
Qy 141 GluValLeuSerAlaSerArgLeuGluLysPheLysHisValArgPheAlaArgIleGln 160
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 421 GAAGTTCTCTCCGCTAGTCGTCTCGAAAAATTCAAACACGTGAGATTTGCAAGAATTCAA 480
Qy 161 AlaSerIleLysAsnLeuTyrThrArgIleAspGlyAsnSerSerThrIleAsnLeuThr 180
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 481 GCGAGCATTAAGAATTTATATACTCGAATTGATGGAAATTCGAGTACGATAAATTTAACT 540
Qy 181 AspTrpLeuGluGluLeuAsnPheGlyLeuIleValLysMetIleAlaGlyLysAsnTyr 200
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 541 GATTGGTTAGAAGAATTGAATTTTGGTCTGATCGTGAAGATGATCGCTGGAAAAAATTAT 600
Qy 201 GluSerGlyLysGlyAspGluGlnValGluArgPheLysLysAlaPheLysAspPheMet 220
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 601 GAATCCGGTAAAGGAGATGAACAAGTGGAGAGATTTAAGAAAGCGTTTAAGGATTTTATG 660
Qy 221 IleLeuSerMetGluPheValLeuTrpAspAlaPheProIleProLeuPheLysTrpVal 240
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 661 ATTTTATCAATGGAGTTTGTGTTATGGGATGCATTTCCAATTCCATTATTTAAATGGGTG 720
Qy 241 AspPheGlnGlyHisValLysAlaMetLysArgThrPheLysAspIleAspSerValPhe 260
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 721 GATTTTCAAGGGCATGTTAAGGCTATGAAAAGGACTTTTAAAGATATAGATTCTGTTTTT 780
Qy 261 GlnAsnTrpLeuGluGluHisIleAsnLysArgGluLysMetGluValAsnAlaGluGly 280
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 781 CAGAATTGGTTAGAGGAACATATTAATAAAAGAGAAAAAATGGAGGTTAATGCAGAAGGG 840
Qy 281 AsnGluGlnAspPheIleAspValValLeuSerLysMetSerAsnGluTyrLeuGlyGlu 300
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 841 AATGAACAAGATTTCATTGATGTGGTGCTTTCAAAAATGAGTAATGAATATCTTGGTGAA 900
Qy 301 GlyTyrSerArgAspThrValIleLysAlaThrValPheSerLeuValLeuAspAlaAla 320
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 901 GGTTACTCTCGTGATACTGTCATTAAAGCAACGGTGTTTAGTTTGGTCTTGGATGCAGCA 960
Qy 321 AspThrValAlaLeuHisIleAsnTrpGlyMetAlaLeuLeuIleAsnAsnGlnLysAla 340
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 961 GACACAGTTGCTCTTCACATAAATTGGGGAATGGCATTATTGATAAACAATCAAAAGGCC 1020
Qy 341 LeuThrLysAlaGlnGluGluIleAspThrLysValGlyLysAspArgTrpValGluGlu 360
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 1021 TTGACGAAAGCACAAGAAGAGATAGACACAAAAGTTGGTAAGGACAGATGGGTAGAAGAG 1080
Qy 361 SerAspIleLysAspLeuValTyrLeuGlnAlaIleValLysGluValLeuArgLeuTyr 380
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 1081 AGTGATATTAAGGATTTGGTATACCTCCAAGCTATTGTTAAAGAAGTGTTACGATTATAT 1140
Qy 381 ProProGlyProLeuLeuValProHisGluAsnValGluAspCysValValSerGlyTyr 400
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 1141 CCACCAGGACCTTTGTTAGTACCACACGAAAATGTAGAAGATTGTGTTGTTAGTGGATAT 1200
Qy 401 HisIleProLysGlyThrArgLeuPheAlaAsnValMetLysLeuGlnArgAspProLys 420
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 1201 CACATTCCTAAAGGGACAAGATTATTCGCAAACGTCATGAAACTGCAACGTGATCCTAAA 1260
Qy 421 LeuTrpSerAspProAspThrPheAspProGluArgPheIleAlaThrAspIleAspPhe 440
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 1261 CTCTGGTCTGATCCTGATACTTTCGATCCAGAGAGATTCATTGCTACTGATATTGACTTT 1320
Qy 441 ArgGlyGlnTyrTyrLysTyrIleProPheGlySerGlyArgArgSerCysProGlyMet 460
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 1321 CGTGGTCAGTACTATAAGTATATCCCGTTTGGTTCTGGAAGACGATCTTGTCCAGGGATG 1380
Qy 461 ThrTyrAlaLeuGlnValGluHisLeuThrMetAlaHisLeuIleGlnGlyPheAsnTyr 480
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 1381 ACTTATGCATTGCAAGTGGAACACTTAACAATGGCACATTTGATCCAAGGTTTCAATTAC 1440
Qy 481 ArgThrProAsnAspGluProLeuAspMetLysGluGlyAlaGlyIleThrIleArgLys 500
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 1441 AGAACTCCAAATGACGAGCCCTTGGATATGAAGGAAGGTGCAGGCATAACTATACGTAAG 1500
Qy 501 ValAsnProValGluLeuIleIleAlaProArgLeuAlaProGluLeuTyr 517
|||||||||||||||||||||||||||||||||||||||||||||||||||
Db 1501 GTAAATCCTGTGGAACTGATAATAGCGCCTCGCCTGGCACCTGAGCTTTAT 1551
RESULT 1
DQ205656
LOCUS DQ205656 1572 bp mRNA linear PLN 18-JAN-2007
DEFINITION Nicotiana tabacum nicotine demethylase mRNA, complete cds.
ACCESSION DQ205656
VERSION DQ205656.1
KEYWORDS .
SOURCE Nicotiana tabacum (common tobacco)
ORGANISM Nicotiana tabacum
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
Spermatophyta; Magnoliopsida; eudicotyledons; Gunneridae;
Pentapetalae; asterids; lamiids; Solanales; Solanaceae;
Nicotianoideae; Nicotianeae; Nicotiana.
REFERENCE 1 (bases 1 to 1572)
AUTHORS Xu,D., Shen,Y., Chappell,J., Cui,M. and Nielsen,M.T.
TITLE Biochemical and molecular characterizations of nicotine demethylase
in tobacco
JOURNAL Physiol. Plantarum 129, 307-319 (2007)
REFERENCE 2 (bases 1 to 1572)
AUTHORS Xu,D., Shen,Y. and Nielsen,M.T.
TITLE Direct Submission
JOURNAL Submitted (14-SEP-2005) USSTC, 100 West Putnam Avenue, Greenwich,
CT 06830, USA
FEATURES Location/Qualifiers
source 1..1572
/organism="Nicotiana tabacum"
/mol_type="mRNA"
/cultivar="4407"
/db_xref="taxon:4097"
CDS 9..1562
/note="CYP450"
/codon_start=1
/product="nicotine demethylase"
/protein_id="ABB36475.1"
/translation="MLSPIEAIVGLVTFTFLFFFLWTKKSQKPSKPLPPKIPGGWPVI
GHLFHFNDDGDDRPLARKLGDLADKYGPVFTFRLGLPLVLVVSSYEAVKDCFSTNDAI
FSNRPAFLYGDYLGYNNAMLFLANYGPYWRKNRKLVIQEVLSASRLEKFKHVRFARIQ
ASIKNLYTRIDGNSSTINLTDWLEELNFGLIVKMIAGKNYESGKGDEQVERFKKAFKD
FMILSMEFVLWDAFPIPLFKWVDFQGHVKAMKRTFKDIDSVFQNWLEEHINKREKMEV
NAEGNEQDFIDVVLSKMSNEYLGEGYSRDTVIKATVFSLVLDAADTVALHINWGMALL
INNQKALTKAQEEIDTKVGKDRWVEESDIKDLVYLQAIVKEVLRLYPPGPLLVPHENV
EDCVVSGYHIPKGTRLFANVMKLQRDPKLWSDPDTFDPERFIATDIDFRGQYYKYIPF
GSGRRSCPGMTYALQVEHLTMAHLIQGFNYRTPNDEPLDMKEGAGITIRKVNPVELII
APRLAPELY
Alignment Scores:
Length: 1572
Score: 2733.00 Matches: 517
Percent Similarity: 100.0% Conservative: 0
Best Local Similarity: 100.0% Mismatches: 0
Query Match: 100.0% Indels: 0
Gaps: 0
US-18-810-533-2 (1-517) x DQ205656 (1-1572)
Qy 1 MetLeuSerProIleGluAlaIleValGlyLeuValThrPheThrPheLeuPhePhePhe 20
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 9 ATGCTTTCTCCCATAGAAGCCATTGTAGGACTAGTAACCTTCACATTTCTCTTCTTCTTC 68
Qy 21 LeuTrpThrLysLysSerGlnLysProSerLysProLeuProProLysIleProGlyGly 40
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 69 CTATGGACAAAAAAATCTCAAAAACCTTCAAAACCCTTACCACCGAAAATCCCCGGAGGA 128
Qy 41 TrpProValIleGlyHisLeuPheHisPheAsnAspAspGlyAspAspArgProLeuAla 60
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 129 TGGCCGGTAATCGGCCATCTTTTCCACTTCAATGACGACGGCGACGACCGTCCATTAGCT 188
Qy 61 ArgLysLeuGlyAspLeuAlaAspLysTyrGlyProValPheThrPheArgLeuGlyLeu 80
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 189 CGAAAACTCGGAGACTTAGCTGACAAATACGGCCCCGTTTTCACTTTTCGGCTAGGCCTT 248
Qy 81 ProLeuValLeuValValSerSerTyrGluAlaValLysAspCysPheSerThrAsnAsp 100
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 249 CCCCTTGTCTTAGTTGTAAGCAGTTACGAAGCTGTAAAAGACTGTTTCTCTACAAATGAC 308
Qy 101 AlaIlePheSerAsnArgProAlaPheLeuTyrGlyAspTyrLeuGlyTyrAsnAsnAla 120
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 309 GCCATTTTTTCCAATCGTCCAGCTTTTCTTTACGGCGATTACCTTGGCTACAATAATGCC 368
Qy 121 MetLeuPheLeuAlaAsnTyrGlyProTyrTrpArgLysAsnArgLysLeuValIleGln 140
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 369 ATGCTATTTTTGGCCAATTACGGACCTTACTGGCGAAAAAATCGAAAATTAGTTATTCAG 428
Qy 141 GluValLeuSerAlaSerArgLeuGluLysPheLysHisValArgPheAlaArgIleGln 160
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 429 GAAGTTCTCTCCGCTAGTCGTCTCGAAAAATTCAAACACGTGAGATTTGCAAGAATTCAA 488
Qy 161 AlaSerIleLysAsnLeuTyrThrArgIleAspGlyAsnSerSerThrIleAsnLeuThr 180
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 489 GCGAGCATTAAGAATTTATATACTCGAATTGATGGAAATTCGAGTACGATAAATTTAACT 548
Qy 181 AspTrpLeuGluGluLeuAsnPheGlyLeuIleValLysMetIleAlaGlyLysAsnTyr 200
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 549 GATTGGTTAGAAGAATTGAATTTTGGTCTGATCGTGAAGATGATCGCTGGAAAAAATTAT 608
Qy 201 GluSerGlyLysGlyAspGluGlnValGluArgPheLysLysAlaPheLysAspPheMet 220
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 609 GAATCCGGTAAAGGAGATGAACAAGTGGAGAGATTTAAGAAAGCGTTTAAGGATTTTATG 668
Qy 221 IleLeuSerMetGluPheValLeuTrpAspAlaPheProIleProLeuPheLysTrpVal 240
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 669 ATTTTATCAATGGAGTTTGTGTTATGGGATGCATTTCCAATTCCATTATTTAAATGGGTG 728
Qy 241 AspPheGlnGlyHisValLysAlaMetLysArgThrPheLysAspIleAspSerValPhe 260
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 729 GATTTTCAAGGGCATGTTAAGGCTATGAAAAGGACTTTTAAAGATATAGATTCTGTTTTT 788
Qy 261 GlnAsnTrpLeuGluGluHisIleAsnLysArgGluLysMetGluValAsnAlaGluGly 280
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 789 CAGAATTGGTTAGAGGAACATATTAATAAAAGAGAAAAAATGGAGGTTAATGCAGAAGGG 848
Qy 281 AsnGluGlnAspPheIleAspValValLeuSerLysMetSerAsnGluTyrLeuGlyGlu 300
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 849 AATGAACAAGATTTCATTGATGTGGTGCTTTCAAAAATGAGTAATGAATATCTTGGTGAA 908
Qy 301 GlyTyrSerArgAspThrValIleLysAlaThrValPheSerLeuValLeuAspAlaAla 320
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 909 GGTTACTCTCGTGATACTGTCATTAAAGCAACGGTGTTTAGTTTGGTCTTGGATGCAGCA 968
Qy 321 AspThrValAlaLeuHisIleAsnTrpGlyMetAlaLeuLeuIleAsnAsnGlnLysAla 340
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 969 GACACAGTTGCTCTTCACATAAATTGGGGAATGGCATTATTGATAAACAATCAAAAGGCC 1028
Qy 341 LeuThrLysAlaGlnGluGluIleAspThrLysValGlyLysAspArgTrpValGluGlu 360
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 1029 TTGACGAAAGCACAAGAAGAGATAGACACAAAAGTTGGTAAGGACAGATGGGTAGAAGAG 1088
Qy 361 SerAspIleLysAspLeuValTyrLeuGlnAlaIleValLysGluValLeuArgLeuTyr 380
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 1089 AGTGATATTAAGGATTTGGTATACCTCCAAGCTATTGTTAAAGAAGTGTTACGATTATAT 1148
Qy 381 ProProGlyProLeuLeuValProHisGluAsnValGluAspCysValValSerGlyTyr 400
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 1149 CCACCAGGACCTTTGTTAGTACCACACGAAAATGTAGAAGATTGTGTTGTTAGTGGATAT 1208
Qy 401 HisIleProLysGlyThrArgLeuPheAlaAsnValMetLysLeuGlnArgAspProLys 420
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 1209 CACATTCCTAAAGGGACAAGATTATTCGCAAACGTCATGAAACTGCAACGTGATCCTAAA 1268
Qy 421 LeuTrpSerAspProAspThrPheAspProGluArgPheIleAlaThrAspIleAspPhe 440
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 1269 CTCTGGTCTGATCCTGATACTTTCGATCCAGAGAGATTCATTGCTACTGATATTGACTTT 1328
Qy 441 ArgGlyGlnTyrTyrLysTyrIleProPheGlySerGlyArgArgSerCysProGlyMet 460
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 1329 CGTGGTCAGTACTATAAGTATATCCCGTTTGGTTCTGGAAGACGATCTTGTCCAGGGATG 1388
Qy 461 ThrTyrAlaLeuGlnValGluHisLeuThrMetAlaHisLeuIleGlnGlyPheAsnTyr 480
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 1389 ACTTATGCATTGCAAGTGGAACACTTAACAATGGCACATTTGATCCAAGGTTTCAATTAC 1448
Qy 481 ArgThrProAsnAspGluProLeuAspMetLysGluGlyAlaGlyIleThrIleArgLys 500
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 1449 AGAACTCCAAATGACGAGCCCTTGGATATGAAGGAAGGTGCAGGCATAACTATACGTAAG 1508
Qy 501 ValAsnProValGluLeuIleIleAlaProArgLeuAlaProGluLeuTyr 517
|||||||||||||||||||||||||||||||||||||||||||||||||||
Db 1509 GTAAATCCTGTGGAACTGATAATAGCGCCTCGCCTGGCACCTGAGCTTTAT 1559
Conclusion
No claim is allowed.
Contact information
Any inquiry concerning this communication or earlier communications from the examiner should be directed to WAYNE ZHONG whose telephone number is (571)270-0311. The examiner can normally be reached 8:30am to 5:00pm EST.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Bratislav Stankovic, can be reached on 571-270-0305. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/Wayne Zhong/
Primary Examiner, Art Unit 1662
Prosecution Insights